69 related articles for article (PubMed ID: 30556601)
1. Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells.
Hartman ML; Sztiller-Sikorska M; Czyz M
Mol Carcinog; 2019 Apr; 58(4):588-602. PubMed ID: 30556601
[TBL] [Abstract][Full Text] [Related]
2. Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing.
Artomov M; Stratigos AJ; Kim I; Kumar R; Lauss M; Reddy BY; Miao B; Daniela Robles-Espinoza C; Sankar A; Njauw CN; Shannon K; Gragoudas ES; Marie Lane A; Iyer V; Newton-Bishop JA; Timothy Bishop D; Holland EA; Mann GJ; Singh T; Daly MJ; Tsao H
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29522175
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling.
Cifola I; Pietrelli A; Consolandi C; Severgnini M; Mangano E; Russo V; De Bellis G; Battaglia C
PLoS One; 2013; 8(5):e63597. PubMed ID: 23704925
[TBL] [Abstract][Full Text] [Related]
4. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.
Shain AH; Garrido M; Botton T; Talevich E; Yeh I; Sanborn JZ; Chung J; Wang NJ; Kakavand H; Mann GJ; Thompson JF; Wiesner T; Roy R; Olshen AB; Gagnon A; Gray JW; Huh N; Hur JS; Busam KJ; Scolyer RA; Cho RJ; Murali R; Bastian BC
Nat Genet; 2015 Oct; 47(10):1194-9. PubMed ID: 26343386
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.
Chowers G; Abebe-Campino G; Golan H; Vivante A; Greenberger S; Soudack M; Barkai G; Fox-Fisher I; Li D; March M; Battig MR; Hakonarson H; Adams D; Dori Y; Dagan A
Pediatr Res; 2023 Dec; 94(6):1911-1915. PubMed ID: 35246606
[TBL] [Abstract][Full Text] [Related]
6. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Newell F; Kong Y; Wilmott JS; Johansson PA; Ferguson PM; Cui C; Li Z; Kazakoff SH; Burke H; Dodds TJ; Patch AM; Nones K; Tembe V; Shang P; van der Weyden L; Wong K; Holmes O; Lo S; Leonard C; Wood S; Xu Q; Rawson RV; Mukhopadhyay P; Dummer R; Levesque MP; Jönsson G; Wang X; Yeh I; Wu H; Joseph N; Bastian BC; Long GV; Spillane AJ; Shannon KF; Thompson JF; Saw RPM; Adams DJ; Si L; Pearson JV; Hayward NK; Waddell N; Mann GJ; Guo J; Scolyer RA
Nat Commun; 2019 Jul; 10(1):3163. PubMed ID: 31320640
[TBL] [Abstract][Full Text] [Related]
7. A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma.
Gureghian V; Herbst H; Kozar I; Mihajlovic K; Malod-Dognin N; Ceddia G; Angeli C; Margue C; Randic T; Philippidou D; Nomigni MT; Hemedan A; Tranchevent LC; Longworth J; Bauer M; Badkas A; Gaigneaux A; Muller A; Ostaszewski M; Tolle F; Pržulj N; Kreis S
Cancer Gene Ther; 2023 Oct; 30(10):1330-1345. PubMed ID: 37420093
[TBL] [Abstract][Full Text] [Related]
8. NRAS
Pastura P; McDaniel CG; Alharbi S; Fox D; Coleman B; Malik P; Adams DM; Le Cras TD
Pediatr Blood Cancer; 2024 May; ():e31032. PubMed ID: 38711167
[TBL] [Abstract][Full Text] [Related]
9. Alternative Splicing of RAD6B and Not RAD6A is Selectively Increased in Melanoma: Identification and Functional Characterization.
Gajan A; Martin CE; Kim S; Joshi M; Michelhaugh SK; Sloma I; Mittal S; Firestine S; Shekhar MPV
Cells; 2019 Nov; 8(11):. PubMed ID: 31683936
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues.
Peralta S; Marcinczyk MM; Katt WP; Duhamel GE
Front Vet Sci; 2023; 10():1281022. PubMed ID: 37901104
[TBL] [Abstract][Full Text] [Related]
11. Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
Spain L; Coulton A; Lobon I; Rowan A; Schnidrig D; Shepherd STC; Shum B; Byrne F; Goicoechea M; Piperni E; Au L; Edmonds K; Carlyle E; Hunter N; Renn A; Messiou C; Hughes P; Nobbs J; Foijer F; van den Bos H; Wardenaar R; Spierings DCJ; Spencer C; Schmitt AM; Tippu Z; Lingard K; Grostate L; Peat K; Kelly K; Sarker S; Vaughan S; Mangwende M; Terry L; Kelly D; Biano J; Murra A; Korteweg J; Lewis C; O'Flaherty M; Cattin AL; Emmerich M; Gerard CL; Pallikonda HA; Lynch J; Mason R; Rogiers A; Xu H; Huebner A; McGranahan N; Al Bakir M; Murai J; Naceur-Lombardelli C; Borg E; Mitchison M; Moore DA; Falzon M; Proctor I; Stamp GWH; Nye EL; Young K; Furness AJS; Pickering L; Stewart R; Mahadeva U; Green A; Larkin J; Litchfield K; Swanton C; Jamal-Hanjani M; ; Turajlic S
Cancer Discov; 2023 Jun; 13(6):1364-1385. PubMed ID: 36977461
[TBL] [Abstract][Full Text] [Related]
12. Characterization of proteome-size scaling by integrative omics reveals mechanisms of proliferation control in cancer.
Jones I; Dent L; Higo T; Roumeliotis T; Arias Garcia M; Shree H; Choudhary J; Pedersen M; Bakal C
Sci Adv; 2023 Jan; 9(4):eadd0636. PubMed ID: 36696495
[TBL] [Abstract][Full Text] [Related]
13. Molecular Characterization of Juxtaglomerular Cell Tumors: Evidence of Alterations in MAPK-RAS Pathway.
Lobo J; Canete-Portillo S; Pena MDCR; McKenney JK; Aron M; Massicano F; Wilk BM; Gajapathy M; Brown DM; Baydar DE; Matoso A; Rioux-Leclerq N; Pan CC; Tretiakova MS; Trpkov K; Williamson SR; Rais-Bahrami S; Mackinnon AC; Harada S; Worthey EA; Magi-Galluzzi C
Mod Pathol; 2024 Apr; 37(6):100492. PubMed ID: 38614322
[TBL] [Abstract][Full Text] [Related]
14. Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.
Senses KM; Ghasemi M; Akbar MW; Isbilen M; Fallacara AL; Frankenburg S; Schenone S; Lotem M; Botta M; Gure AO
Medchemcomm; 2017 Jan; 8(1):88-95. PubMed ID: 28670440
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.
Zhao X; Little P; Hoyle AP; Pegna GJ; Hayward MC; Ivanova A; Parker JS; Marron DL; Soloway MG; Jo H; Salazar AH; Papakonstantinou MP; Bouchard DM; Jefferys SR; Hoadley KA; Ollila DW; Frank JS; Thomas NE; Googe PB; Ezzell AJ; Collichio FA; Lee CB; Earp HS; Sharpless NE; Hugo W; Wilmott JS; Quek C; Waddell N; Johansson PA; Thompson JF; Hayward NK; Mann GJ; Lo RS; Johnson DB; Scolyer RA; Hayes DN; Moschos SJ
Front Oncol; 2018; 8():584. PubMed ID: 30662871
[No Abstract] [Full Text] [Related]
16. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
17. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
18. An open-label, multicentre safety study of vemurafenib in patients with BRAF
Larkin J; Brown MP; Arance AM; Hauschild A; Queirolo P; Vecchio MD; Ascierto PA; Krajsová I; Schachter J; Neyns B; Garbe C; Sileni VC; Mandalà M; Gogas H; Espinosa E; Hospers G; Lorigan P; Nyakas M; Guminski A; Liszkay G; Rutkowski P; Miller W; Donica M; Makrutzki M; Blank C
Eur J Cancer; 2019 Jan; 107():175-185. PubMed ID: 30580112
[TBL] [Abstract][Full Text] [Related]
19. ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma.
Wu CE; Koay TS; Esfandiari A; Ho YH; Lovat P; Lunec J
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30577494
[TBL] [Abstract][Full Text] [Related]
20. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.
Boussemart L; Johnson A; Schrock AB; Pal SK; Frampton GM; Fabrizio D; Chalmers Z; Lotem M; Gibney G; Russell J; Chmielowski B; Ross JS; Stephens PJ; Miller VA; Ali SM
J Am Acad Dermatol; 2019 Jun; 80(6):1780-1782. PubMed ID: 30576761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
